why choose us

First received: July 28, 2023

Clinical Trial: Study of Allogeneic Blood-derived Natural Killer Cells to Evaluate Safety and Tolerability in Cancer Refractory to Conventional Therapy

Study Status: Completed

Recruit Status: RECRUITING

Condition: Pathologically Confirmed Cancer Refractory to Conventional Therapy

Study Type: INTERVENTIONAL


Official Title: A Phase 1, Open-Label, Dose Escalation Study of Allogeneic Blood-derived Natural Killer Cells to Evaluate Safety and Tolerability in Participants With Pathologically Confirmed Cancer Refractory to Con

Brief Summary: The goal of this clinical trial is to test SNK02 in participants with pathologically confirmed cancer that is refractory to conventional therapy.The main questions it aims to answer are:Is SNK02 safety and tolerable when administered weekly as an intravenous infusionWhat is the maximum dose that is tolerated of SNK02 Participants will be administered SNK02 weekly for 8 weeks and undergo medical evaluation to provide initial clinical safety data for the treatment of cancer with allogeneic NK cells as a monotherapy…

Read more